ConvaTec stock eases from recent highs as valuation debate builds
Published on 08/29/2026 at 10:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ConvaTec Group PLC (ISIN GB00BD3VFW73) stock edged lower on August 28, 2026, with the shares closing at 227.60p on the London market as investors reassessed the recent run-up and valuation backdrop in the healthcare sector.
Market data for August 28, 2026, show ConvaTec finishing the session at 227.60p, down 0.87% on the day as the stock underperformed the broader FTSE 100 Index, which gained 0.29% over the same trading day. This mild decline came after the shares traded in a narrow intraday range between 226.60p and 231.00p, underscoring a period of consolidation after their climb earlier in the year.
Latest share price and trading context
On August 28, 2026, a real-time overview of major U.K. healthcare names listed ConvaTec at a last price of 227.60p, with an intraday high of 231.00p and a low of 226.60p, and a one-day change of -2.00p, equivalent to -0.87% on that session. Trading volume stood at 23.62 million shares, indicating active participation despite the modest price move.
The broader London market closed higher on August 28, 2026, yet ConvaTec shares declined 0.96% to 227.60p at the end of the session, highlighting that the stock lagged index-level performance even as risk appetite persisted elsewhere. That divergence suggests some investors were willing to lock in gains or rotate capital, even while the overall FTSE 100 advanced.
Valuation gap versus analyst targets
Alongside the latest quote, a detailed data page summarizing ConvaTec’s metrics lists an average analyst price objective of 4.033 USD per share as of late August 2026. In the same dataset, the last closing price is shown at 3.078 USD for the company’s equity, implying that the average target sits around 31% above the most recent closing level when expressed in dollar terms.
Another valuation-oriented overview of U.K. equities identifies ConvaTec as trading at £2.296 per share against an average target of £4.25, implying a discount of roughly 46% to that consensus level. This spread between current share price and target values indicates that equity analysts collectively expect upside over their forecast horizon, even though the shares have already delivered gains over the past year.
For investors, the combination of a modest pullback on August 28, 2026, and a wide gap to published targets frames ConvaTec as a name where sentiment is balancing shorter-term profit-taking against longer-term growth expectations. The exact timing at which such a valuation gap might close is uncertain, but quantitatively the discount is substantial in both pound and dollar terms.
Recent fundamentals and sector positioning
In the most recent period covered by the valuation compendium, ConvaTec is grouped among larger U.K. healthcare companies with a market capitalization ranking that places it firmly in the established mid to large-cap band. The same overview lists the company within a healthcare cohort that has generally delivered positive one-year returns, with ConvaTec’s share price progression contributing to that pattern and supporting the view that its business has sustained investor interest.
While the latest day’s sources focus primarily on valuation and price levels rather than detailed quarterly figures, the inclusion of ConvaTec in panels of significant healthcare issuers suggests that the market continues to treat its fundamentals as solid enough to justify analyst coverage and formal price targets. Historically, the company has reported steady growth in revenue and maintained dividends, and these longer-term patterns serve as background to the valuation discussion even though the specific historical numbers fall outside the nine-month freshness window and therefore are not treated as current metrics.
Within this context, one comparative highlight is the one-year return profile across major U.K. healthcare stocks. The same dataset that lists ConvaTec’s current share price also details one-year performance for peers, illustrating that ConvaTec’s trajectory fits within a broader theme where healthcare has provided resilient returns relative to some cyclicals. This comparative dimension reinforces why analysts assign relatively high target prices: they are extrapolating ongoing demand for medical products and technologies into future earnings streams.
Esteem Body with Leak Defense: a core product
ConvaTec’s investment case is underpinned by its portfolio of medical devices and technologies, including the Esteem Body with Leak Defense ostomy system, which the company has described as a product designed to give users greater confidence by combining a flexible one-piece pouch with engineered leakage protection. In previous communications, ConvaTec has emphasized that this line extends its established Esteem offerings and targets patients who need discreet, reliable solutions for everyday use.
The Esteem Body with Leak Defense product sits within ConvaTec’s wider advanced wound care and ostomy care segments, where the company has long sought to differentiate through comfort, adherence, and patient-centric design. For investors, such a product illustrates how ConvaTec is attempting to align engineering and clinical insight to support quality-of-life improvements, thereby potentially sustaining demand and pricing power in its core markets.
Stock level and investor takeaway
ConvaTec’s primary listing is on the London Stock Exchange, with trading in pence sterling and secondary data often expressed in U.S. dollars for global comparison. As of the close on August 28, 2026, the shares traded at 227.60p, with the 52-week range documented between 195.10p and 295.20p, placing the latest level near the mid-point of that band. This positioning relative to the 52-week range shows that, although the stock has pulled back from higher levels, it remains above its lows and retains scope for movement in either direction as new fundamentals and guidance emerge.
For retail investors monitoring ConvaTec stock into the next reporting cycle, the key numerical points are the modest single-day decline of -0.87% on August 28, 2026, the active trading volume of 23.62 million shares, and the quantified valuation gap of more than 30% between recent closing prices and the consolidated analyst target in dollar terms. These figures together frame the company as a healthcare issuer whose stock is consolidating while the market debates how quickly the gap between price and fundamental expectations should narrow.
Read more on ConvaTec
Further details on ConvaTec’s business, strategy, and formal financial reports are available from the company’s own investor information hub. That site provides access to annual and interim results, capital markets presentations, and information on dividends and corporate governance, offering deeper context for the share performance and valuation metrics discussed here.
Fact box: ConvaTec Group PLC
Company: ConvaTec Group PLC
ISIN: GB00BD3VFW73
Ticker: CTEC
Exchange: London Stock Exchange
Price (as of August 28, 2026, close): 227.60p
Market cap: data compiled in late August 2026 place ConvaTec among the larger U.K. healthcare names by equity value
Sector / Industry: Healthcare - Medical devices and technologies
Index membership: FTSE 100
